New shot aims to stop catheter clots without blood thinners
NCT ID NCT07498517
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a single dose of gruticibart, a monoclonal antibody, can prevent blood clots that often form when a central venous catheter is placed. About 90 adults getting a catheter will receive either the drug or a placebo. The goal is to see if gruticibart reduces clots and the need for risky blood thinners.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gruticibart (a monoclonal antibody)
What this could lead to
If it works, this could offer a way to prevent catheter-related blood clots without the bleeding risks of standard blood thinners.
What could go wrong
This is an early Phase 2 trial with only 90 participants, so results may not apply to everyone. The drug could still cause bleeding or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact